Checkpoint inhibitors in advanced nonsmall-cell lung cancer; a Bayesian network meta-analysis

Basit Öğe Kaydı
dc.contributor.authorBozcuk, Hakan
dc.contributor.authorYildirim, Mustafa
dc.contributor.authorSever, Ozlem
dc.contributor.authorMutlu, Hasan
dc.contributor.authorArtac, Mehmet
dc.date.accessioned2024-02-23T14:37:53Z
dc.date.available2024-02-23T14:37:53Z
dc.date.issued2020
dc.departmentNEÜen_US
dc.description.abstractBackground: Checkpoint inhibitors (CPIs) have improved survival compared to chemotherapy alone in advanced nonsmall-cell lung cancer (NSCLC). This article aims to compare indirect evidence and rank the effect of different CPIs in this setting. Materials and Methods: In this network meta-analysis, we searched for trials comparing CPIs in advanced NSCLC. Figures for survival endpoints were extracted. In addition, a network meta-regression analysis was carried out. Results: A total of 9220 patients from 16 trials were included in the analysis. In the first-line setting, for the overall survival endpoint, the chemotherapy + Pembrolizumab combination had the highest effectivity rank probability as compared to chemotherapy (hazard ratio = 0.788, 95% credential interval = 0.728-0.855). For the second-line setting, and also for the efficacy in terms of progression-free survival, various CPIs and their combinations were ranked. Conclusion: Some degree of differences in terms of efficacy exists between different types, dosages, settings, and combinations of CPI. We quantify these differences to guide clinical practice.en_US
dc.identifier.doi10.4103/jcrt.JCRT_450_19
dc.identifier.endpage837en_US
dc.identifier.issn0973-1482
dc.identifier.issn1998-4138
dc.identifier.issue4en_US
dc.identifier.pmid32930126en_US
dc.identifier.scopus2-s2.0-85091053450en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage828en_US
dc.identifier.urihttps://doi.org/10.4103/jcrt.JCRT_450_19
dc.identifier.urihttps://hdl.handle.net/20.500.12452/16255
dc.identifier.volume16en_US
dc.identifier.wosWOS:000585412200021en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWolters Kluwer Medknow Publicationsen_US
dc.relation.ispartofJournal Of Cancer Research And Therapeuticsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAtezolizumaben_US
dc.subjectAvelumaben_US
dc.subjectCheckpoint Inhibitoren_US
dc.subjectNivolumaben_US
dc.subjectNonsmall-Cell Lung Canceren_US
dc.subjectPembrolizumaben_US
dc.titleCheckpoint inhibitors in advanced nonsmall-cell lung cancer; a Bayesian network meta-analysisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu